Treatment of slow-channel congenital myasthenic syndrome with fluoxetine

C. Michel Harper, Takayasu Fukodome, Andrew G. Engel

Research output: Contribution to journalArticlepeer-review

104 Scopus citations


The authors found that fluoxetine significantly shortens at 5 μM/L and nearly normalizes at 10 μM/L the prolonged opening bursts of slow-channel congenital myasthenic syndrome (SCCMS) acetylcholine receptors (AChR) expressed in fibroblasts. Prompted by this observation, they treated two SCCMS patients allergic to quinidine with up to 80 to 120 mg of fluoxetine per day over 3 years (serum fluoxetine + norfluoxetine levels 8 to 11 μM/L). Both patients showed marked subjective and objective improvement by quantitative muscle strength testing and electromyography.

Original languageEnglish (US)
Pages (from-to)1710-1713
Number of pages4
Issue number10
StatePublished - May 27 2003

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Treatment of slow-channel congenital myasthenic syndrome with fluoxetine'. Together they form a unique fingerprint.

Cite this